Authors:
Mehrabi, MR
Ekmekcioglu, C
Stanek, B
Thalhammer, T
Tamaddon, F
Pacher, R
Steiner, GE
Wild, T
Grimm, M
Spieckermann, PG
Mall, G
Glogar, HD
Citation: Mr. Mehrabi et al., Angiogenesis stimulation in explanted hearts from patients pre-treated with intravenous prostaglandin E-1, J HEART LUN, 20(4), 2001, pp. 465-473
Authors:
Hulsmann, M
Sturm, B
Pacher, R
Berger, R
Bojic, A
Frey, B
Stanek, B
Citation: M. Hulsmann et al., Long-term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction, J HEART LUN, 20(11), 2001, pp. 1174-1180
Authors:
Stanek, B
Frey, B
Hulsmann, M
Berger, R
Sturm, B
Strametz-Juranek, J
Bergler-Klein, J
Moser, P
Bojic, A
Hartter, E
Pacher, R
Citation: B. Stanek et al., Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction, J AM COL C, 38(2), 2001, pp. 436-442
Authors:
Berger, R
Stanek, B
Hulsmann, M
Frey, B
Heher, S
Pacher, R
Neunteufl, T
Citation: R. Berger et al., Effects of endothelin A receptor blockade on endothelial function in patients with chronic heart failure, CIRCULATION, 103(7), 2001, pp. 981-986
Authors:
Sturm, B
Pacher, R
Strametz-Juranek, J
Berger, R
Frey, B
Stanek, B
Citation: B. Sturm et al., Effect of beta 1 blockade with atenolol on progression of heart failure inpatients pretreated with high-dose enalapril, EUR J HE FA, 2(4), 2000, pp. 407-412
Citation: B. Stanek, Optimising management of patients with advanced heart failure - The importance of preventing progression, DRUG AGING, 16(2), 2000, pp. 87-106
Authors:
Berger, R
Strecker, K
Hulsmann, M
Frey, B
Pacher, R
Stanek, B
Citation: R. Berger et al., Experience with beta-blocker therapy in patients with advanced heart failure evaluated for HTx, J HEART LUN, 19(11), 2000, pp. 1081-1088
Authors:
Frey, B
Pacher, R
Locker, G
Bojic, A
Hartter, E
Woloszczuk, W
Stanek, B
Citation: B. Frey et al., Prognostic value of hemodynamic vs big endothelin measurements during long-term IV therapy in advanced heart failure patients, CHEST, 117(6), 2000, pp. 1713-1719
Citation: R. Pacher et B. Stanek, Ambulatory vasodilator therapy in heart failure: systematic review of the literature and personal observational experience, EUR J HE FA, 1(3), 1999, pp. 263-268
Authors:
Stanek, B
Sturm, B
Frey, B
Hulsmann, M
Bojic, A
Berger, R
Rodler, S
Locker, G
Grimm, M
Laufer, G
Pacher, R
Citation: B. Stanek et al., Bridging to heart transplantation: Prostaglandin E-1 versus prostacyclin versus dobutamine, J HEART LUN, 18(4), 1999, pp. 358-366
Authors:
Frey, B
Zuckermann, A
Koller-Strametz, J
Rodler, S
Hulsmann, M
Stanek, B
Grimm, M
Laufer, G
Pacher, R
Citation: B. Frey et al., Effects of continuous, long-term therapy with prostaglandin E1 preoperatively on outcome after heart transplantation, TRANSPLAN P, 31(1-2), 1999, pp. 80-81
Authors:
Stanek, B
Frey, B
Berger, R
Hartter, E
Pacher, R
Citation: B. Stanek et al., Value of sequential big endothelin plasma concentrations to predict rapid worsening of chronic heart failure, TRANSPLAN P, 31(1-2), 1999, pp. 155-157
Authors:
Wimmer, A
Stanek, B
Kubecova, L
Vitovec, J
Spinar, J
Yilmaz, N
Kos, T
Hartter, E
Frey, B
Pacher, R
Citation: A. Wimmer et al., Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure, JPN HEART J, 40(3), 1999, pp. 321-334
Authors:
Sturm, B
Quittan, M
Wiesinger, GF
Stanek, B
Frey, B
Pacher, R
Citation: B. Sturm et al., Moderate-intensity exercise training with elements of step aerobics in patients with severe chronic heart failure, ARCH PHYS M, 80(7), 1999, pp. 746-750